57
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Co-morbidity in prostate cancer

&
Pages 132-136 | Received 20 Jun 2000, Accepted 04 Jul 2000, Published online: 06 Jul 2009
 

Abstract

With the widespread use of prostate-specific antigen (PSA) screening, prostate cancer has become the mostly common diagnosed malignancy in the United States. Because prostate cancer preferably affects elderly males and usually progresses slowly, there is an increasing interest in the significance of co-morbid conditions complicating the course of the disease. Several scores have been applied to assess the co-morbidity in newly diagnosed prostate cancer patients and to estimate the impact of concomitant diseases on survival. Patients in their eighth decade of life, diagnosed with well or moderately differentiated localized prostate cancer and suffering from severe co-morbidity, are likely to die of causes other than the malignancy. Clinical trials evaluating different treatment modalities for localized prostate cancer need controlling and stratification for age and co-morbidity. The life expectancy of patients with only one controlled concomitant disorder, however, is not significantly compromised and the management of these patients remains controversial.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.